Based on mounting evidence proving that n-3-PUFA have beneficial effects on people affected by depression, schizophrenia, and bipolar disorder115–117 in combination with data on the correlation between mTOR and other pathologies (e.g., cancer), Shirooie and colleagues118 reviewed that mTOR can be one of n-3-PUFA’s targets to treat neurodegenerative diseases by regulating essential cellular processes such as apoptosis and autophagy. This evidence concerns the gene MTOR and major depressive disorder.